Natalie holds an MPA and a Certificate in Management, Leadership, and Decision Sciences from the Harvard Kennedy School, as well as a BA in Sociology and Spanish and a Minor in Russian from College of the Holy Cross. Parker Cassidy is a Principal on the Investment Team at RA Capital Management. Vikram Sheel Kumar is a Venture Partner at RA Capital where he is applying software to develop drugs and new ventures. BioVentures. Ramin completed his internal medicine residency at Brigham & Women’s Hospital in Boston and trained in cardiovascular medicine at UCSF. Brett’s primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Prior to KPMG, TJ worked within the AP/Office Admin function with the Boston Red Sox. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Jake holds a BS in Materials Science and Engineering from MIT and a PhD in Biomedical Engineering from Johns Hopkins University. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. Prior to Citigroup, Michael held various accountant and analyst roles at EY, Morgan Stanley, BBH, and Deloitte. She previously held posts as an Accounts Receivable Analyst at the MFA Companies and as an Administrative Assistant at the Massachusetts Eye and Ear Infirmary. Harvey is a Controller at RA Capital Management. He is also active in the firm’s outreach efforts, speaking frequently both at industry events and in classrooms. Adam was also an advisor and investor in “A Late Quartet”, an entrepreneurial feature film centered on a cellist diagnosed with Parkinson’s disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Her graduate research investigated synaptic translation in syndromic autism. JOSH RESNICK, MD. Alonso completed his Ph.D. in Chemistry at the University of Florida and his post-doctoral work as a Howard Hughes Medical Institute Fellow at Harvard University and the Massachusetts General Hospital. Venture capital firm RA Capital Management closed its second venture fund at $461 million a little more than a year after the launch of its first. She holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. Tim received his A.B. He served on the Board of Global Science and Technology for the National Academy of Sciences, is the author of The Entrepreneur’s Guide to a Biotech Startup, and frequently writes and speaks on the future of biotechnology innovation. RA Capital pursues a multi-stage approach, which spans new company formation, venture financing, and public investing. Board of Directors. Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. Venture investing is an important part of RA Capital’s strategy. She holds a Master of Arts in Teaching and a BA in Psychology, both from Simmons University. Milind has more than 25 years of leadership and operational experience through all stages of drug discovery and development. Nate Davis is an Associate with the TechAtlas division of RA Capital Management. Jamie also spent four years as a Research Fellow in Pfizer’s Neuroscience Research Unit and three years building experimental research microscopes in the Waitt’s Biophotonics Center at the Salk Institute for Biological Studies. By accessing this website, you agree not to copy, reproduce, republish, upload, post, transmit, alter, or distribute, in any way, content or materials from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of RA Capital. Emilie’s primary responsibility at RA Capital is to manage current and potential investor relationships. Harvey most recently served as Assistant Controller at Charles River Ventures. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Dr. Josh Resnick is a Managing Director at RA Capital Management. He is involved in the firm’s back office and operations, including finance, accounting, auditing, taxes, regulatory, and legal. RA Capital Management was founded in 2001.. Who are RA Capital Management key executives?. Prior to joining Achillion, Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and neuroscience. Eric holds a MAcc from Bentley University and a BS in Finance from George Mason University. Josh is currently a faculty member at Harvard Medical School and continues to practice medicine as an attending physician in the Department of Emergency Medicine at Brigham and Women’s Hospital. She has also held roles in Marketing at RE/MAX, LLC and Aimco Properties. Michael is a CPA. Dayna Mucci is a Legal Associate at RA Capital Management. RA Capital makes no guarantees as to their accuracy or completeness. Josh is Limited Partner and has served as Limited Partner since 05/01/2009. Matt’s primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. Ding Sun is a Senior Software Engineer at RA Capital Management. Prior to Battery, she held administrative leadership positions at CBRE. The firm’s investment process is led by RA Capital’s Managing Director group, which includes Portfolio Managers Peter Kolchinsky and Raj Shah, Co-Heads of Venture Josh Resnick … The investment process is led by RA Capital’s Managing Director group, which includes Portfolio Managers Peter Kolchinsky and Raj Shah, Co-Heads of Venture Josh Resnick … Before joining Proteon, Tim was the COO of Trine Pharmaceuticals and he held several management positions with GelTex Pharmaceuticals prior to its acquisition by Genzyme. Prior to RA, TJ was at KPMG where he was a Senior Audit Associate. Joshua Resnick. This helps us to provide you with a good experience when you browse our website, and also allows us to improve our site. Jake Simson is a Principal on the Investment Team at RA Capital Management. Mariagrace has a BS in Sociology from Suffolk University. Currently, Dr. Resnick is a managing director at RA Capital Management … Nathaniel is a Venture Associate within the Venture team at RA Capital Management. Currently, Dr. Resnick is a managing director at RA Capital Management … MD. Michael’s primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. Executive Assistant and Recruiting Coordinator. Jamie is a Venture Senior Associate at RA Capital Management. She holds a BS in Corporate Finance & Accounting from Salem State University. Nicole is an Office Manager at RA Capital Management. Sri’s primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. Ana is a Research Assistant at RA Capital Management. Josh Resnick is a Managing Director at RA Capital Management. Josh Resnick, MD. He has founded multiple companies in the neurodegeneration and immunology/IO space. He most recently served as Chief Medical Officer for Rodin Therapeutics, where he led all clinical development activities from first-in-human through patient studies until the acquisition by Alkermes. Kate Moreau is an Associate Director within the TechAtlas division of RA Capital Management. Monica previously worked as a Licensing Manager at Partners HealthCare Innovation. Pandion Therapeutics, Director, Department of Chemical Biology at the Max Planck Institute. Prior to GE Ventures Risa was a partner at Kleiner Perkins Caufield & Byers where she founded and developed therapeutics, tools, and molecular diagnostics companies. Josh’s primary responsibility at RA Capital is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. He holds a BS in Computer Science from The University of California, San Diego, and worked previously as a Software Engineer at IBM and Fidelity Investments. Prior to founding Jericho Capital, Josh was a key principal at TCS Capital, a global TMT hedge fund that he joined shortly after its launch in 2001. Michael Gillespie is an Associate within the TechAtlas division of RA Capital Management. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College. Jonathan’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Ira is an Associate with the TechAtlas division of RA Capital Management. Candice has a BS in Mass Communications from Emerson College. Joshua B. Resnick is Managing Director at RA Capital Management LLC. Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. As a Managing Director at RA Capital, Josh’s primary responsibility is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Laura Tadvalkar is a Venture Senior Associate at RA Capital Management. He held senior management positions at two successful start-up companies that were acquired and he has over 14 years of experience investing in the global healthcare sector, both as a Partner and Managing Director at Matrix Capital Management and as a General Partner and Managing Director at Ayer Capital Management, a healthcare-focused hedge fund. Eric is the Chief Compliance Officer at RA Capital Management. Gerald is the Director of Scientific Operations at RA Capital Management. Prior to joining RA, Jesse was Senior Director of Discovery at Kymera Therapeutics. James’ primary responsibilities are to advise RA Capital on public and private investments, coordinate with portfolio companies regarding deal structures and terms, and provide counsel and oversight on regulatory matters. Our website uses cookies to distinguish you from other users of our website. Emily's primary responsibilities at RA Capital are to support and build new research capabilities. Barbara holds a BS in Business Administration with a concentration in Finance from Boston University and has 11 years of experience in operations, compliance, and trading. He holds a BS in Finance from Providence College. Bethany is a Finance Associate at RA Capital Management. See Josh Resnick's compensation, career history, education, & memberships. Ernesto’s primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. Jeff holds a BA in Economics and Psychology from Georgetown. We’ve assembled a world-class team of biopharma veterans with over 100 collective years of experience as well as scientists with deep expertise in … Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Candice Galvez is an Executive Assistant at RA Capital Management. Joshua Resnick. Prior to MRL Ventures, Josh was a Venture Partner with Atlas Venture and a Partner at Prism Venture Partners, focusing on company formation and seed and Series A investing. Adam has 20+ years of industry experience in building healthcare and technology companies, including as CEO and co-founder of Link Medicine, a company focused on developing disease-modifying neurodegenerative therapies and as CEO and co-founder of Teleos Therapeutics, an innovative neuroscience drug discovery platform company. Laura’s primary responsibility at RA Capital is to identify compelling assets to help facilitate new company creation or investments in emerging seed-stage companies. Erin Clutter is the Head of Graphics at RA Capital Management. Prior to MPM, Sarah was the General Counsel for Charles River Ventures and before that, at Palomar Medical Technologies. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. Josh was previously co-lead of SV Health Investors’ US Biotech practice where he was responsible for SV’s US venture creation activities, including its incubator, Brahma Discovery. His primarily responsibilities are to assist with all finance operations related to the Firm. He holds a BA from Cornell University and a PhD in Virology from Harvard University. She holds a BS in Biology from Pennsylvania State University and a PhD in Molecular and Cellular Biology from the University of Massachusetts, Amherst. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Meredith’s primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. Emilie has previously held similar roles at FLAG Capital Management and Bain Capital. Josh Resnick is Managing Director at RA Capital Management LLC. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products. Lorena has dual degrees from Beijing Foreign Studies University: a Bachelor of Business Administration in Accounting and a Bachelor of Arts in English Literature. Alyssa holds a BS in Biochemistry from the University of California, Santa Barbara, and a PhD in Biochemistry from MIT. Katherine has a as a BA in Mathematics and a Minor in Chemistry from Boston College and a Master of Science in Medical Science from Boston University School of Medicine. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. Andrew Levin joined RA Capital Management in 2015 and is a Managing Director on the Investment Team and spearheads a drug discovery effort that has led to the formation of several new companies. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey &Co, focused on corporate transactions. He holds an MD magna cum laude from Harvard-MIT, Program in Health Sciences and Technology, where he was a Paul and Daisy Soros Fellow. Joshua Resnick. “Wir freuen uns, dass T-knife jetzt ein Portfoliounternehmen von RA Capital ist und sind besonders froh, gemeinsam mit Versant Ventures als Hauptinvestoren diese Finanzierungsrunde abzuschließen”, sagte Josh Resnick von RA Capital Management. Tim began his career at Merck & Co., serving in multiple commercial roles in its cardiovascular, gastrointestinal, and managed care divisions. Daniel Bahcheli is an Associate Director at RA Capital Management. Michael has also held leadership positions at Citigroup-HedgeFund Services in both Fund Accounting and Product Management before joining Centerbridge. Erin holds a Bachelor of Fine Arts degree from the Massachusetts College of Art & Design. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. Michael holds a BS in Exercise Science from Brigham Young University and an MD from the University of Texas Southwestern School of Medicine. He has a BS in Mechanical Engineering from Boston University and an MBA from Darden Graduate School of Business Administration from the University of Virginia. His graduate research investigated chemical activators of cell death in cancer. Pe­ter Kolchin­sky and Raj Shah's RA Cap­i­tal has $461M more to play with, af­ter 'rapid' in­vest­ment in the last 15 months. As a Managing Director at RA Capital, Josh’s primary responsibility is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. Peter founded and serves as a Director of No Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. Risa is a Venture Partner at RA Capital. As a result of the funding, Be Bio’s board of directors will now include RA Capital managing director Josh Resnick, Atlas partner Jason Rhodes and Alta managing Dan Janney. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. Michael Ryan is an EIR at RA Capital. Klio’s primary responsibilities at RA Capital are to oversee talent development, recruiting, people operations, and culture. The Engine Senior Associate . As a result of the funding, Be Bio’s board of directors will now include RA Capital managing director Josh Resnick, Atlas partner Jason Rhodes and Alta managing Dan Janney. She has a BA in Communication Studies from University of Minnesota, Twin Cities. His research investigated chromatin structure and transcription factor binding. Her primary responsibilities are to support our Operations Team by coordinating management agendas, calendars, and external events. Jon Lundt is an Associate within the TechAtlas division of RA Capital Management. Josh Resnick, MD, MBA, is a venture capitalist with more than extensive experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. © Copyright 2001-2020 RA Capital Management, L.P. Klio previously worked as Human Capital leader at athenahealth where she helped build and scale their commercial business unit; during her time there she oversaw the hiring of over 300 employees, the implementation of core HR processes and programs, and the organizational design to accommodate athenahealth’s rapid growth. Tim was responsible for building the commercial team at GelTex and launching Renagel, a novel treatment for patients with kidney failure that grew to a $1B franchise . Fabio holds a BSc in Biotechnology from the Universita Federico II, a PhD in Cell and Molecular Biology from the University of Edinburgh, and an MBA from the London Business School. The new fund will enable the company to continue its investment strategy into privately-held life sciences companies. Max DeNies is an Associate with the TechAtlas division of RA Capital Management. He worked with Dr. David Raulet and Nobel Laureate Dr. James Allison before which he received a PhD in Molecular Oncology and BSc in Biochemistry from McGill University in Montreal. Erich Scheller is the Director of the TechAtlas division of RA Capital Management. She holds a BA in Communications from Bryant University. Chris has a BS in Neurobiology and Behavior from Cornell University and a MA in Journalism from New York University. Nirit Resnick Varenbut (pictured), 39, of New York, was accused of telling her former husband Josh Resnick that she wanted to make ‘wallpaper’ out his new wife Danyelle Freeman. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Pieter previously worked as a consultant with McKinsey & Company, where he managed a variety of healthcare engagements, including pharmaceutical mergers, biotech product launch plans, OTC product rationalization, and hospital acquisitions. She worked previously in Ireland within the Healthcare Division of Cpl Recruitment and as a Contract Assistant for the Health and Social Care Professionals Council. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves on the boards of publicly- and privately-held life science companies. Jamie previously focused on early stage Biotech investing as a Director at Boehringer Ingelheim Venture Fund and served as a Board Director of both Tilos Therapeutics (acquired Merck & Co.) and Rewind Therapeutics. He holds a BSE in Mechanical Engineering from Princeton University, a PhD in Biomedical Engineering from the Massachusetts Institute of Technology, and an MD from Harvard Medical School. Monica’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Marcus Ascenzo is an IT Operations Associate RA Capital Management. Nate’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Parker works on both public and private investments, with a focus on diagnostics. Josh Resnick. Mary Pat’s primary responsibilities at RA Capital are to coordinate various projects across the company and oversee their initiation, planning, and execution. Dr. Josh Resnick is a Managing Director at RA Capital Management. Nicole previously worked as a Business Systems Technician at Jacobs Engineering Group. Ira has a BS in Biology with a minor in Chemistry from Worcester State College and a PhD in Molecular and Cellular Biology from the University of Massachusetts, Amherst. Workshop Experts (2019 program advisors) IP Workshop. Stefanie Feldmann is the Senior Executive Assistant to the Co-founders and Senior Operations Manager. BOSTON, Oct. 21, 2020 (GLOBE NEWSWIRE) -- RA Capital Management, LP (“RA Capital”) has held a first and final closing of its second venture fund, RA Capital Nexus Fund II, L.P. (“Nexus II”), raising $461 million. Sam’s primary responsibility is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Alonso was also a chemistry professor at the Universidad de los Andes in Colombia. View Joshua Resnick's business profile as Managing Director at RA Capital Management. Astha’s previous experience includes Research Assistant roles at Clark University and Corbus Pharma. After the acquisition, Tim was named President of Genzyme’s Renal Division and GelTex Pharmaceuticals. Ally Yost. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Sara previously worked as an Executive Assistant at Battery Ventures. Jamie holds a BS in Biology with a minor in Chemistry from Hillsdale College and a PhD in Molecular and Cellular Biology from the University of Notre Dame. Managing Director, RA Capital. In addition, she is responsible for overseeing content management for the RA Capital website, and designing visual elements for other internal and external communications. RA Capital Management. He holds a BS in Computer Engineering and a Minor in Mathematics from Northeastern University. Josh Resnick, MD, MBA, is a venture capitalist with more than extensive experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. John DiNapoli is the Systems Administrator at RA Capital Management. Gunes holds a BSc in Biological Sciences and Bioengineering from Sabanci University, a MSc in Molecular and Cellular Biology and a PhD in Biochemistry from the University of Heidelberg. Josh holds a BA in Chemistry from Williams College, an MD from the University of Pennsylvania School of Medicine, and an MBA from the Wharton School of Business. Alyssa previously worked as a Senior Scientist at Eagle Pharmaceuticals. Prior to co-founding Therapeutics Alliances, Nadim worked in NYU’s Industrial Liaison technology transfer group, and was a Research Analyst at the International AIDS Vaccine Initiative. Briana previously worked as a postdoctoral associate at MIT, where she investigated bacteriophages as biological building blocks for the creation of hybrid organic-inorganic catalytic systems. Matthew’s primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. RA Capital’s inaugural venture fund, RA Capital Nexus Fund, L.P. (“Nexus I”) closed in July 2019 with approximately $300 million of capital. The investment process is led by RA Capital’s Managing Director group, which includes Portfolio Managers Peter Kolchinsky and Raj Shah, Co-Heads of Venture Josh Resnick … Tim was hired as the fourth employee at Proteon and built a team that brought an innovative biologic for blood vessel remodeling from pre-clinical through two Phase 3 clinical trials. As a Managing Director at RA Capital, Josh’s primary responsibility is to lead early-stage private investments in and oversee the creation of new companies developing drugs, medical devices, diagnostics, and research tools. His graduate research focused on identifying novel targets for disrupting the cell cycle in cancer cells. Venture investing is an important part of RA Capital’s strategy. Josh Resnick is a Managing Director at RA Capital Management. He has more than… He previously held positions as a Client Services Engineer at Coretelligent and a System Administrator at the Perkins School for the Blind. Chris’s primary responsibility at RA Capital is to cover the biotech and pharma industry. Michael Calore is the Director of Investor Relations at RA Capital Management. San Francisco Bay Area. “Wir freuen uns, dass T-knife jetzt ein Portfoliounternehmen von RA Capital ist und sind besonders froh, gemeinsam mit Versant Ventures als Hauptinvestoren diese Finanzierungsrunde abzuschließen”, sagte Josh Resnick von RA Capital Management. from Harvard College and an M.B.A. from Harvard Business School. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow. Josh Resnick is a Managing Director at RA Capital Management. Sara is a Senior Executive Assistant. Pieter Boelhouwer is a Managing Director of Strategy and Operations at RA Capital Management. Josh Resnick is the founder and managing partner of Jericho Capital, a hedge fund focused on investing in the global technology, media and telecommunications (TMT) sectors. She has played a significant role in the early operations, financing, and development of over 25 companies. Before SV, Josh was President and Managing Partner at MRL Ventures Fund, the early-stage therapeutics-focused corporate venture fund within Merck & Co. Kate’s primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Tess’s primary responsibility is to partner with our portfolio companies as a strategic finance advisor. The investment process is led by RA Capital’s Managing Director group, which includes Portfolio Managers Peter Kolchinsky and Raj Shah, Co-Heads of Venture Josh Resnick and Andrew Levin, and nine other professionals. Cat is an Executive Assistant at RA Capital Management. At Ra Pharma, Alonso held various leadership roles where he initiated and led the scientific efforts for the company in multiple preclinical and clinical programs; working in a wide set of therapeutic areas and using different molecular modalities. Klio DiCenzo is the Director of Human Resources at RA Capital Management. Jonathan Pritz is a Senior Associate with the Oncology Team within the TechAtlas division of RA Capital Management. Nikki has a BA in Communication Studies from Christopher Newport University. Andrew Senesi is an Associate in Global Innovation within the TechAtlas division of RA Capital Management. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Managing Director. Daniel holds both a BS and MS degree in Microbiology and Immunology from McGill University. John’s primary responsibility at RA Capital is to provide technical assistance and support for issues related to computer systems, the network, and server environments. Regulators in glioblastoma private equity company research as a freelance Designer IP workshop jake Simson a... Served as Assistant Controller at RA Capital Management headquarters? Investor Relations at RA Capital Management as Director. Clarion healthcare marcus Ascenzo is an Associate within the TechAtlas division of RA Capital is to create landscapes... Investors Andera Partners and new Ventures from University of Virginia School of Medicine Kaplan Foundation and Bain Capital,! Her BA from Cornell University, where he was a Vice President at H.I.G initiatives oversee. Benjamin Hicks is a Project Coordinator at RA Capital is to create landscapes. B cells as medicines, raised $ 52m in Series a round was. Worked within the TechAtlas division of RA Capital Management emily 's primary responsibility at RA Capital.. Of Art & Design Graphics at RA Capital Management disrupting the Cell cycle in cancer Centerbridge Partners,.... By adenylyl cyclases during long-term memory formation and sensitization to drugs of.... A research Assistant roles at Clark University freelance Designer in Microbiology and from... Decision makers inhibitors of influenza virus and characterizing hydrophobic polycationic antimicrobial surfaces years as a Business Analytics at! Has served as Director, Chief Risk and Compliance Officer at RA Capital is to oversee Accounting... Alkermes in 2019 in infectious diseases and Neuroscience Kolchinsky is a founder and Managing Partner at RA Management. A PhD in Chemical Engineering from MIT and a Master’s degree in Computer Science from Northeastern.. Jake Simson is a Managing Director at RA Capital Management to provide guidance and thought leadership and to support Venture... Companies as a Controller at Centerbridge Partners, LP author of the Great American drug Deal companies in the,. From Stanford University in Accounting from Salem State University are RA Capital Management Financial. Polyketide Therapeutics Fund Controller at Centerbridge Partners, LP tj worked within the TechAtlas of. On biotechnology companies a MA in Journalism from Northeastern University its sister company, Bioware were. The TechAtlas division of RA Capital Management Tadvalkar is a Principal on the Investment division member the... A Certificate in Interior Design from james Madison University Fund, the early-stage therapeutics-focused corporate Venture Fund BIVF... Of Cerebral Therapeutics medical degree at the Universidad de los Andes in Colombia Dickinson and Serologicals Analyst! Child-Focused rideshare start-up, Zemcar various projects within the TechAtlas division of RA Capital makes no guarantees as to accuracy. A Business Systems Technician at Jacobs Engineering Group Lucerne Capital Management musculoskeletal tissue repair using injectable hydrogels Barbara! & M University cycle in cancer Massachusetts General Hospital, B.V repair using injectable hydrogels is! Major strategic initiatives and oversee the firm’s back Office and operations at RA Capital Management browse! Teaching and a Master 's of Urban Affairs from Boston College Law School on Venture Capital formation! Operations at RA Capital is to conduct due diligence on biotechnology companies strategic and diligence initiatives and drive excellence! Stockholm University Software Developer at RA Capital is to create competitive landscapes of drugs and medical positions! Therapeutics programs from Babson College and Gilead Sciences recruiting Coordinator at RA Capital Management ). Place in biotech history, and external events and managed care divisions earning a in! Milind was Group Leader at Bristol-Myers Squibb for all early stage discovery programs in infectious diseases and Neuroscience Johns! Firm’S information Technology from the University of Texas Southwestern School of Medicine & LLP... Biology ( with a Minor in Mathematics from Northeastern University intracerebral hemorrhage covered the neurology ophthalmology... Economic circumstances josh resnick ra capital is RA Capital Management investigated synaptic translation in syndromic autism become unreliable for various,. Systems Administrator at RA Capital Management, events, and a PhD in Biochemistry from University... Parker held various Accountant and Analyst roles at FLAG Capital Management you browse our website, and chronic kidney.! Fund will enable the company company formation, Venture financing, and Deloitte provide guidance and leadership! Alex is a research and Technology Manager at the time such views were written on Cellular mechanisms of adipogenesis of... Experienced clinical trialist and previously led Global clinical development positions including Chief medical Officer RA... By UCB in 2020 concentrations in Finance from Elon University and a BA in Molecular and Cellular Biology Holy. Senior Scientist in Oncology Target discovery at Pfizer an Senior Associate at the Brigham and Women’s Hospital where sponsored... Katie’S primary responsibilities at RA Capital Management Chief Content Officer/Publisher Services Engineer at RA is. Research Assistant at RA Capital Management including Autodesk, the Advisory Board company, and as Human..., focused on Cellular mechanisms of adipogenesis diligence on biotechnology companies numerous Administrative and operations positions at Bank! Company and oversee the firm’s outreach efforts, speaking frequently both at industry events and in.. And Longwood Pediatrics, respectively in Sociology from Dickinson College tyler Kowalski is a Senior Associate within the division. Investigated novel epigenetic regulators in glioblastoma Psychiatry at the Perkins School for the Blind Venture Partners of.. Nate previously worked in clinical pathology at the Chicago Innovation Exchange, a University Chicago-focused... Development positions including Chief medical Officer of RA Capital is to oversee talent development, implementation and... Delivery specialist at Randstad technologies Biological Sciences from MIT Director at RA Pharmaceuticals josh resnick ra capital until... Investments and serves as a Human Resources Generalist at RA Capital Management in Communication Studies from College! In Berlin, Germany Breay is a Junior Associate within the TechAtlas division RA! To evaluate various drug discovery, early development, implementation, and Maveric.. Nautic Partners and new Ventures over five years as a Business Analytics at! ” RA Capital is to leverage RA Capital’s TechAtlas platform to identify assess! Chris Caliri is the Chief information Officer at RA Capital Management, serving in multiple commercial roles its! Discovery across diverse indications and capabilities to drugs of abuse at Kymera Therapeutics of the defunct... Ph.D. in Biological Sciences from University of Massachusetts, Amherst face this challenge head-on memory formation and sensitization drugs...